1887

Abstract

The performance of the Fungitell assay was investigated in 100 patients with haematological malignancy undergoing chemotherapy who developed antibiotic-unresponsive neutropenic fever (AUNF). Serum --glucan (BG) concentrations were significantly elevated on the first day of AUNF and all subsequent alternate days to day 10 in 38 patients who developed an invasive fungal infection (IFI) compared to 42 patients remaining free of such infections. The mean and median values of BG were 171.9±29.6 and 95.8 pg ml, respectively, for patients with IFI and 64.4±17.1 and 32.9 pg ml for patients with only AUNF (<0.0001). The differences remained significant over the 10 days despite antifungal therapy. The occurrence of ≥2 sequential concentrations of ≥80 pg ml (‘positive’ test) was found to give the best overall option for diagnosis, with an accuracy of 81.3 %, sensitivity of 86.8 %, positive predictive value of 76.7 % and negative predictive value of 86.5 %. Of the patients with an IFI, 78 % developed a positive test at or before the clinical diagnosis was made – this occurred at a mean (range) of 1.25 (−14 to +14) days prior to the IFI diagnosis. By starting sampling of blood from the first day of neutropenia rather than from the first day of AUNF, 50 % of the patients with subsequent IFI would have been identified 5 days earlier. Increasing sampling to daily from alternate-day frequency did not further improve this earlier timing of an IFI diagnosis. A greater proportion of patients with persistent high levels of BG without overt IFI had severe enterocyte damage or mucositis than those with lower levels of BG without IFI (=0.002). If the results of the initial BG test had been acted on to change antifungal therapy, discontinuation would have been inappropriate in 30 % of patients and would have delayed definitive antifungal therapy. Although the findings for the cohort of patients studied are very useful, there is inter-patient variability in the test's performance. An holistic diagnostic approach is therefore necessary to interpret the test results optimally. Future studies should address this in further detail as well as the impact of empirical antifungal drug use and patient outcome.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47479-0
2008-03-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/3/287.html?itemId=/content/journal/jmm/10.1099/jmm.0.47479-0&mimeType=html&fmt=ahah

References

  1. Ascioglu S., Rex J., de Pauw B., Bennett J., Bille J., Crokaert F., Denning D., Donnelly J., Edwards J. other authors 2002; Defining opportunistic infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14 [CrossRef]
    [Google Scholar]
  2. Associates of Cape Cod 2004; Glucan assay for (1,3)-β- d -glucan in serum (FUNGITELL™) Instructions for use.
    [Google Scholar]
  3. Caillot D., Casasnovas O., Bernard A., Couaillier J. F., Durand C., Cuisenier B., Solary E., Piard F., Petrella T. other authors 1997; Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomography scan and surgery. J Clin Oncol 15:139–147
    [Google Scholar]
  4. Caillot D., Couaillier J., Bernard A., Casasnovas O., Denning D., Mannone L., Lopez J., Couillault G., Piard F. other authors 2001; Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19:253–259
    [Google Scholar]
  5. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G. other authors 2002; CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242 [CrossRef]
    [Google Scholar]
  6. De Pauw B. E. 2005; Between over- and undertreatment of invasive fungal disease. Clin Infect Dis 41:1251–1253 [CrossRef]
    [Google Scholar]
  7. Ellis M. 2004; Preventing microbial translocation in haematological malignancy. Br J Haematol 125:282–293 [CrossRef]
    [Google Scholar]
  8. EORTC International Antimicrobial Therapy Cooperative Group 1989; Empiric antifungal therapy in febrile neutropenic patients. Am J Med 86:668–672 [CrossRef]
    [Google Scholar]
  9. Farag S. S., Ruppert A. S., Mrózek K., Mayer R. J., Stone R. M., Carroll A. J., Powell B. L., Moore J. O., Pettenati M. J. other authors 2005; Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 23:482–493
    [Google Scholar]
  10. Fridkin S. K. 2005; The changing face of fungal infections in health care settings. Clin Infect Dis 41:1455–1460 [CrossRef]
    [Google Scholar]
  11. Garey K. W., Rege M., Pai M. P., Mingo D. E., Suda K. J., Turpin R. S., Bearden D. T. 2006; Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43:25–31 [CrossRef]
    [Google Scholar]
  12. Hughes W. T., Armstrong D., Bodey G. P., Bow E. J., Brown A. E., Calandra T., Feld R., Pizzo P. A., Rolston K. V. I. other authors 2002; 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751 [CrossRef]
    [Google Scholar]
  13. Kami M., Kishi Y., Hamaki T., Kawabata M., Kashima T., Masumoto T., Oki Y., Tanaka Y., Sawada S. other authors 2002; The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. An autopsy-based retrospective study of 48 patients. Mycoses 45:287–294 [CrossRef]
    [Google Scholar]
  14. Kelaher A. 2006; Two non-invasive diagnostic tools for invasive aspergillosis: (1,3)- β -d-glucan and the galactomannan assay. Clin Lab Sci 19:222–224
    [Google Scholar]
  15. Krause W., Matheis H., Wulf K. 1969; Fungaemia and funguria after oral administration of Candida albicans . Lancet 1:598–599
    [Google Scholar]
  16. Maertens J., Verhaegen J., Lagrou K., van Eldere J., Boogaerts M. 2001; Screening for circulating galactomannan as a non-invasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97:1604–1610 [CrossRef]
    [Google Scholar]
  17. Maertens J., Theunissen K., Verhoef G., Verschakelen J., Lagrou K., Verbeken E., Wilmer A., Verhaegen J., Boogaerts M., van Eldere J. 2005; Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41:1242–1250 [CrossRef]
    [Google Scholar]
  18. Martino R., Viscoli C. 2005; Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 132:138–154
    [Google Scholar]
  19. Medical Research Council Working Party on Leukemia in Adults 2006; Medical Research Council Acute Lymphoblastic Leukemia Trial XII (ULALL XII), Version 4.1. February 2006. Joint Trial with Eastern Cooperative Oncology Group (ECOG) – E2993. Protocol for Adults with ALL. Modified for Intrathecal Therapy and Philadelphia Positive ALL. July 2002 Revised May 2005, February 2006. Available at http://www.ctsu.ox.ac.uk/projects/ukallxii/
    [Google Scholar]
  20. Odabasi Z., Mattiuzzi G., Estey E., Kantarjian H., Saeki F., Ridge R. J., Ketchum P. A., Finkelman M. A., Rex J. H., Ostrosky-Zeichner L. 2004; β -d-Glucan as a diagnostic adjunct for invasive fungal infections: validation, cut-off development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39:199–205 [CrossRef]
    [Google Scholar]
  21. Ostrosky-Zeichner L., Alexander B. D., Kett D. H., Vasquez J., Pappas P. G., Saeki F., Ketchum P. A., Wingard J., Schiff R. other authors 2005; Multicenter clinical evaluation of the (1,3)- β -d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41:654–659 [CrossRef]
    [Google Scholar]
  22. Pazos C., Moragues M., Quindos G., Ponton J., del Palacio A. 2006; Diagnostic potential of (1→3)- β -d-glucan and anti- Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol 23:209–215 [CrossRef]
    [Google Scholar]
  23. Pfeiffer C. D., Fine J. P., Safdar N. 2006; Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42:1417–1427 [CrossRef]
    [Google Scholar]
  24. Pizzo P. A., Robichaud K. J., Gill F. A., Witebsky F. G. 1982; Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101–107 [CrossRef]
    [Google Scholar]
  25. Verweij P. E., Figueroa J., van Burik J., Holdom M. D., Dei-Cas E., Gomez B. L., Mendes-Giannini M. 2000; Clinical applications of non-culture based methods for the diagnosis and management of opportunitic and endemic mycoses. Med Mycol 38:161–171 [CrossRef]
    [Google Scholar]
  26. Walsh T. J., Finberg R. W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., Pappas P., Seibel N., Greenberg R. N. other authors 1999; Liposomal amphotericin B for empirical therapy in patients with persisting fever and neutropenia. N Engl J Med 340:764–771 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47479-0
Loading
/content/journal/jmm/10.1099/jmm.0.47479-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error